oncolytic viral therapy
Jump to navigation
Jump to search
Clinical trials
- 2 patients with relapsing drug-refractory myeloma & multiple glucose-avid plasmacytomas were treated by intravenous infusion of 10E11 TCID50 (50% tissue culture infectious dose) infectious units of MV-NIS*
- both patients responded to therapy with M protein reduction & resolution of bone marrow plasmacytosis
- patient experienced durable complete remission at all disease sites
- tumor targeting documented by NIS-mediated radioiodine uptake in virus-infected plasmacytomas
* MV-NIS: measles virus encoding human sodium iodide symporter (NIS)
More general terms
References
- ↑ Russell SJ et al Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy. Mayo Clinic Proceedings. May 13, 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24835528 <Internet> http://www.mayoclinicproceedings.org/article/S0025-6196%2814%2900332-2/fulltext
Bell JC Taming Measles Virus to Create an Effective Cancer Therapeutic. Mayo Clinic Proceedings. May 13, 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24835529 <Internet> http://www.mayoclinicproceedings.org/article/S0025-6196%2814%2900368-1/fulltext